Search Results

You are looking at 1 - 10 of 93 items for :

  • "Dabrafenib" x
  • Refine by Access: All x
Clear All
Full access

Unusual Adverse Events in a Patient With BRAF-Mutated Non–Small Cell Lung Cancer Treated With BRAF/MEK Inhibition

Rohan Maniar, Stephanie M. Gallitano, Sameera Husain, Golnaz Moazami, Michael J. Weiss, and Catherine A. Shu

painful eruption over the bilateral lower extremities. First-line treatment with a BRAF inhibitor, dabrafenib at 150 mg twice daily, and an MEK inhibitor, trametinib at 2 mg daily, had been initiated 3 months prior. She had no pertinent dermatologic

Full access

Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non–Small Cell Lung Cancer

John A. Sharp, Daniel Jones, Julia K. Rotow, Panos M. Fidias, Erin Bertino, and Dwight H. Owen

. Although the combination of dabrafenib and trametinib—agents targeting BRAF and MEK, respectively—has demonstrated promising activity in metastatic NSCLC harboring class I BRAF mutations, specifically V600E, 8 its role in the treatment of class II and

Full access

Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade Glioma

Tanner M. Johanns, Cole J. Ferguson, Patrick M. Grierson, Sonika Dahiya, and George Ansstas

(LGGs; Table 1 ). This report describes the use of combination dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in 2 adults with high-grade gliomas (HGGs). The first patient was treated at time of diagnosis, whereas the second was treated at

Full access

Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma

Silviya K. Meletath, Dean Pavlick, Tim Brennan, Roy Hamilton, Juliann Chmielecki, Julia A. Elvin, Norma Palma, Jeffrey S. Ross, Vincent A. Miller, Philip J. Stephens, George Snipes, Veena Rajaram, Siraj M. Ali, and Isaac Melguizo-Gavilanes

dabrafenib and TTFields resulted in a durable complete response of more than 2 years. Case Presentation We reviewed the medical records of a male patient who is undergoing treatment at the Department of Neuro-Oncology at Baylor University Medical

Full access

CRE24-044: Response to Dabrafenib and Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Metastatic Non–Small Cell Lung Cancer

John Sharp, Daniel Jones, Julia Rotow, Panos Fidias, Erin Bertino, and Dwight Owen

-V600 kinase-activating mutations) is unknown. We report on a patient with metastatic NSCLC (mNSCLC) with a class II BRAF p.N486_P490del variant who had a sustained response to dabrafenib and trametinib (dab/tram). Case: A 79-year-old woman with

Full access

Cotreatment of Hairy Cell Leukemia and Melanoma With the BRAF Inhibitor Dabrafenib

James S. Blachly, Gerard Lozanski, David M. Lucas, Michael R. Grever, Kari Kendra, and Leslie A. Andritsos

small molecule BRAF inhibitor vemurafenib. 7 , 10 The newer BRAF inhibitor dabrafenib has also been approved for use in melanoma. This report presents the first case of the cooccurrence of malignant melanoma and HCL, both harboring the BRAF p

Full access

Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas

Anastasia Drobysheva, Laura J. Klesse, Daniel C. Bowers, Veena Rajaram, Dinesh Rakheja, Charles F. Timmons, Jason Wang, Korgun Koral, Lynn Gargan, Erica Ramos, and Jason Y. Park

treatment of low- and high-grade gliomas with BRAF inhibitors (vemurafenib and dabrafenib). 8 – 13 There is only a single report of 2 patients with PAs who were treated with trametinib, a MAPK pathway inhibitor, 5 and no reports on MAPK pathway

Full access

First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition

Victor T.G. Lin, Lisle M. Nabell, Sharon A. Spencer, William R. Carroll, Shuko Harada, and Eddy S. Yang

was identified. After discussion by the UAB MTB, 1 he was started on targeted therapy with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib, in addition to zoledronic acid for his bony metastases ( Figure 1 ). Dabrafenib and trametinib

Full access

Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer

Rishi Agarwal, Jiang Wang, Keith Wilson, William Barrett, and John C. Morris

dabrafenib and trametinib, and experienced a response. Case Report A 47-year-old woman with a history of moderately severe rheumatoid arthritis treated with infliximab and methotrexate presented with a 1-month history of a rapidly enlarging left neck

Full access

Management of Patients With Advanced Melanoma

Presented by: Genevieve Boland

adjuvant therapy trials of immune checkpoint inhibitors (ICIs) in stage III–IV melanoma and their outcomes. Figure 1. Adjuvant therapy in stage III–IV melanoma. Abbreviations: D/T, dabrafenib + trametinib; DMFS, distant metastasis–free survival; HR